Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT – Get Free Report) saw a significant drop in short interest in the month of September. As of September 30th, there was short interest totaling 18,115 shares, a drop of 77.6% from the September 15th total of 80,940 shares. Approximately 2.0% of the company’s shares are sold short. Based on an average daily volume of 49,113 shares, the short-interest ratio is currently 0.4 days.
Purple Biotech Stock Performance
Shares of NASDAQ:PPBT traded up $0.01 during trading on Monday, reaching $1.34. 20,764 shares of the stock were exchanged, compared to its average volume of 521,392. Purple Biotech has a 12-month low of $1.16 and a 12-month high of $14.10. The firm has a market cap of $1.25 million, a price-to-earnings ratio of -0.06 and a beta of 0.73. The firm’s 50-day moving average price is $1.58 and its 200 day moving average price is $2.44.
Purple Biotech (NASDAQ:PPBT – Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported $1.07 EPS for the quarter, beating the consensus estimate of ($0.98) by $2.05. As a group, equities research analysts forecast that Purple Biotech will post -5.73 EPS for the current year.
Analysts Set New Price Targets
Read Our Latest Stock Report on PPBT
About Purple Biotech
Purple Biotech Ltd. is an Israel-based clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research programs are designed to address mechanisms that contribute to tumor growth, immune evasion and resistance to existing treatments.
Purple Biotech’s principal product candidates have included CM24, an investigational monoclonal antibody targeting CEACAM1, an immune checkpoint that may help tumors avoid immune-system detection, and NT219, an investigational small-molecule oncology therapy designed to inhibit signaling pathways associated with resistance to cancer treatments.
See Also
- Five stocks we like better than Purple Biotech
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Purple Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Purple Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
